Reply
Yasuji Arase, Mariko Kobayashi, Hiromitsu Kumada – 17 May 2013
Yasuji Arase, Mariko Kobayashi, Hiromitsu Kumada – 17 May 2013
Lawrence H. Young, Katharine J. Henderson, Robert I. White, Guadalupe Garcia‐Tsao – 17 May 2013
Mazen Noureddin, Katherine P. Yates, Ivana A. Vaughn, Brent A. Neuschwander‐Tetri, Arun J. Sanyal, Arthur McCullough, Raphael Merriman, Bilal Hameed, Edward Doo, David E. Kleiner, Cynthia Behling, Rohit Loomba, for the NASH CRN – 17 May 2013 – The characteristics of nonalcoholic fatty liver disease (NAFLD) in elderly patients are unknown. Therefore, we aimed to examine the differences between elderly and nonelderly patients with NAFLD and to identify determinants of nonalcoholic steatohepatitis (NASH) and advanced fibrosis (bridging fibrosis or cirrhosis) in elderly patients.
Mark Deneau, M. Kyle Jensen, John Holmen, Marc S. Williams, Linda S. Book, Stephen L. Guthery – 17 May 2013 – The epidemiology and natural history of pediatric primary sclerosing cholangitis (PSC), autoimmune sclerosing cholangitis (ASC), and autoimmune hepatitis (AIH) are not well characterized. Using multiple, overlapping search strategies followed by a detailed records review, we identified all cases of pediatric PSC, ASC, AIH, and inflammatory bowel disease (IBD) in a geographically isolated region of the United States.
Engin Gürlevik, Bettina Fleischmann‐Mundt, Nina Armbrecht, Thomas Longerich, Norman Woller, Arnold Kloos, Dirk Hoffmann, Axel Schambach, Thomas C. Wirth, Michael P. Manns, Lars Zender, Stefan Kubicka, Florian Kühnel – 17 May 2013 – Complete surgical tumor resection (R0) for treatment of intrahepatic cholangiocarcinoma (ICC) is potentially curative, but the prognosis remains dismal due to frequent tumor recurrence and metastasis after surgery. Adjuvant therapies may improve the outcome, but clinical studies for an adjuvant approach are difficult and time‐consuming for rare tumor entities.
Núria Guañabens, Anna Monegal, Dacia Cerdá, África Muxí, Laia Gifre, Pilar Peris, Albert Parés – 17 May 2013 – Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC). Once‐weekly alendronate improves bone mass and is well tolerated in these patients, but there is a concern because of poor compliance. Therefore, the efficacy, adherence, and safety of monthly ibandronate (150 mg) with weekly alendronate (70 mg) were compared in a randomized, 2‐year study in 42 postmenopausal women with PBC and osteoporosis.
Akihiro Seki, Yoshio Sakai, Takuya Komura, Alessandro Nasti, Keiko Yoshida, Mami Higashimoto, Masao Honda, Soichiro Usui, Masayuki Takamura, Toshinari Takamura, Takahiro Ochiya, Kengo Furuichi, Takashi Wada, Shuichi Kaneko – 17 May 2013 – Cirrhosis is a chronic liver disease that impairs hepatic function and causes advanced fibrosis. Mesenchymal stem cells have gained recent popularity as a regenerative therapy since they possess immunomodulatory functions. We found that injected adipose tissue‐derived stem cells (ADSCs) reside in the liver.
Hua Wang, Dechun Feng, Ogyi Park, Shi Yin, Bin Gao – 17 May 2013 – Alpha‐Galactosylceramide (α‐Galcer), a specific agonist for invariant natural killer T (iNKT) cells, is being evaluated in clinical trials for the treatment of viral hepatitis and liver cancer. However, the results from α‐Galcer treatment are mixed, partially because of the variety of cytokines produced by activated iNKT cells that have an unknown synergistic effect on the progression of liver disease.
Noémie Péan, Isabelle Doignon, Isabelle Garcin, Aurore Besnard, Boris Julien, Bingkaï Liu, Sophie Branchereau, Anne Spraul, Catherine Guettier, Lydie Humbert, Kristina Schoonjans, Dominique Rainteau, Thierry Tordjmann – 17 May 2013 – Many regulatory pathways are involved in liver regeneration after partial hepatectomy (PH) to initiate growth, protect liver cells, and sustain functions of the remnant liver.
14 May 2013